Haoyuan Pharmaceutical

Shanghai Haoyuan Pharmaceutical Co., Ltd. (referred to as "Haoyuan Pharmaceutical", stock code: 688131) was established in 2006, focusing on the research and development of small molecules and novel molecular type drug building blocks and tool compounds, as well as process development and production of APIs, intermediates, and formulations. It is a platform-based high-tech enterprise providing related products and technical services to global pharmaceutical companies and research institutions, from drug discovery to large-scale production of APIs and pharmaceutical intermediates, with approximately 6,000 partners worldwide. Rooted in the biomedical field, Haoyuan Pharmaceutical consistently adheres to innovation-driven R&D as its core, focusing on enhancing the composite capability of its headquarters. With over 3,000 employees, it has built an R&D system centered on the Shanghai headquarters, radiating to Hefei, Yantai, Ma'anshan, Nanjing, and other locations. It has established six core technology platforms, including a high-potency active pharmaceutical ingredient (HPAPI) development platform, a multi-chiral complex drug technology platform, a vitamin D derivative drug API R&D platform, a specialty targeted drug development platform, a pharmaceutical solid-state chemistry research technology platform, and a molecular building blocks and tool compound library development and incubation platform, along with a rich and competitive product pipeline, having filed over a hundred patents cumulatively. In the field of molecular building blocks, the company's product types are relatively novel and comprehensive, making it a significant player in the niche market; in the field of tool compounds, the company holds a leading position domestically with strong international influence; in the field of specialty APIs and intermediates, the company is one of the domestic leading technology platforms for high-difficulty chemical drug synthesis with strong R&D capabilities, and one of the few enterprises in China to overcome the synthesis of Eribulin, known as the "Mount Everest" of synthetic chemistry; in the ADC business sector, the company is one of the earliest enterprises in China to conduct research on ADC-related small molecule products, having built a diverse and rich Payload-Linker finished product library, with advantages such as strong product and intermediate development capabilities, extensive inventory variety, large-scale production, fast supply to the same industry, and high cost-effectiveness. It has successfully assisted in the approval and market launch of China's first ADC Class I anti-cancer new drug for clinical application. Currently, the company has multiple ADC drug-related small molecule products filed with the US FDA DMF, enabling it to provide efficient, high-quality professional CDMO services. After sixteen years of development, the company has been recognized as a High-tech Enterprise, a National Specialized and Innovative "Little Giant" Enterprise, a Shanghai Brand Cultivation Demonstration Enterprise, a Shanghai Enterprise Technology Center, a Shanghai Science and Technology Little Giant Enterprise, and a Shanghai Patent Work Demonstration Enterprise, and has received numerous honors including the 2021 China CDMO Top 20, the 2021 China Pharmaceutical Industry Top 100, and the 2021 China New Economy Enterprise Top 500. In the future, the company will continue to focus on the development strategy of "industrialization, globalization, and branding," adhere to the service tenet of "everything for customers, everything from innovation," closely monitor global biomedical industry development trends, and strive to build an integrated service platform of "drug R&D - intermediates - APIs - formulations," accelerating the empowerment of global partners from preclinical to commercial production, making drug development more efficient, faster to market, and benefiting human health earlier.